Pre-operative Education Modalities to Decrease Opioid Use
Launched by BENAROYA RESEARCH INSTITUTE · Jun 17, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different ways of teaching patients before surgery can help reduce the use of opioid pain medications after a prostate surgery called radical prostatectomy. The study will compare three groups of patients: one group will receive the usual education from their healthcare provider, the second group will get a text handout with information, and the third group will receive both the text handout and a pre-recorded video. Researchers want to see if these educational methods can lead to less reliance on opioids after surgery.
To be eligible for this trial, participants need to be men aged 18 or older who are scheduled to have radical prostatectomy at a specific hospital. They should also be able to give their consent to participate. However, individuals who have been using opioids regularly for more than three months, have a history of substance dependence, or have allergies to certain pain medications cannot join. If you participate, you can expect to receive information about managing pain after your surgery in different formats, and the study will track how much pain medication you use during and after your hospital stay.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18
- • Undergoing RARP at VMMC
- • Consent to participate in the study
- Exclusion Criteria:
- • Long-term opioid use defined as use of opioids on most days for \>3 months
- • History of drug or alcohol dependence
- • Concurrent surgery during radical prostatectomy
- • History of allergy to opioid analgesics, NSAIDs, acetaminophen or local anesthetics
- • Inability or unwillingness to give written informed consent
About Benaroya Research Institute
Benaroya Research Institute (BRI) is a leading nonprofit research organization dedicated to advancing the understanding and treatment of autoimmune diseases, including type 1 diabetes and rheumatoid arthritis. Situated in Seattle, Washington, BRI is renowned for its innovative approach that integrates cutting-edge research, patient care, and clinical trials. The institute fosters collaboration among scientists, clinicians, and patients to translate scientific discoveries into effective therapies. Through its commitment to excellence in research and education, BRI aims to significantly improve patient outcomes and contribute to the global fight against autoimmune disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Una Lee, MD
Principal Investigator
Virginia Mason Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials